Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase in Central Retinal Artery Occlusion Study
2018-002546-36Phase 3Active
- Sponsor
- Oslo University Hospital
- Start
- Jun 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of tenecteplase in central retinal artery occlusion (CRAO), sponsored by Oslo University Hospital. Primary endpoint: Mean change in logMAR visual acuity from baseline to 6 weeks. Started Jun 2019; status: active.
02
Drugs
tenecteplase
03
Conditions
central retinal artery occlusion (CRAO)
Beyond the preview
Go deeper on 2018-002546-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002546-36.